Clinic and genetic predictors in response to erenumab

Background and purpose Erenumab (ERE) is the first anticalcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. A proportion of patients do not adequately respond to ERE. Methods Prospective multicenter study involving 110 migraine patients starting ERE 70 mg mo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of neurology 2022-04, Vol.29 (4), p.1209-1217
Hauptverfasser:	Zecca, Chiara, Cargnin, Sarah, Schankin, Christoph, Giannantoni, Nadia Mariagrazia, Viana, Michele, Maraffi, Isabella, Riccitelli, Gianna Carla, Sihabdeen, Shairin, Terrazzino, Salvatore, Gobbi, Claudio
Format:	Artikel
Sprache:	eng
Schlagworte:	Alleles anti‐CGRP antibodies Calcitonin Confidence intervals Demographics Demography erenumab Genetic diversity Genetic variance Headache Impact tests Migraine Monoclonal antibodies Original Patients Polymerase chain reaction predictors Receptor activity modifying proteins Receptors Regression analysis Regression models Statistical analysis treatment response
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!